Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia
Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia
复制标题
DOI：
10.1016/j.nicl.2014.03.014
复制
发表时间：
2014-01-01
影响因子：
4.2
通讯作者：
Hugdahl, Kenneth
中科院分区：
文献类型：
--
作者：
Falkenberg, Liv E.;Westerhausen, Rene;Hugdahl, Kenneth
精神分裂症的特征是认知功能受损，参与认知控制过程的大脑区域显示出明显的神经元异常。然而，目前尚不清楚异常的神经元反应是否与精神分裂症中代谢物水平上观察到的缺陷直接相关。在这里，17名药物治疗的精神分裂症患者和17名匹配的健康参与者进行功能磁共振成像（fMRI）时，执行听觉认知控制任务，以及质子磁共振波谱（H-1-MRS），以评估静息状态谷氨酸在前扣带皮层。联合fMRI-H-1-MRS分析显示，谷氨酸差异预测皮质血氧水平依赖性（BOLD）反应的患者和对照组。虽然我们发现谷氨酸和患者下顶叶双侧BOLD反应之间呈正相关，但在健康对照参与者中，相应的相关性为负。此外，谷氨酸水平预测患者的任务表现，因此较低的谷氨酸水平与认知控制功能受损有关。这在健康对照组中未观察到。这些发现表明，精神分裂症患者有一个谷氨酸相关的支持认知控制功能的大脑网络失调。这可能是未来研究精神分裂症认知症状的药物治疗的目标。(C)2014作者爱思唯尔公司出版。
Schizophrenia is characterized by impaired cognitive functioning, and brain regions involved in cognitive control processes show marked glutamatergic abnormalities. However, it is presently unclear whether aberrant neuronal response is directly related to the observed deficits at the metabolite level in schizophrenia. Here, 17 medicated schizophrenia patients and 17 matched healthy participants underwent functional magnetic resonance imaging (fMRI) when performing an auditory cognitive control task, as well as proton magnetic resonance spectroscopy (H-1-MRS) in order to assess resting-state glutamate in the anterior cingulate cortex. The combined fMRI-H-1-MRS analysis revealed that glutamate differentially predicted cortical blood-oxygen level-dependent (BOLD) response in patients and controls. While we found a positive correlation between glutamate and BOLD response bilaterally in the inferior parietal lobes in the patients, the corresponding correlation was negative in the healthy control participants. Further, glutamate levels predicted task performance in patients, such that lower glutamate levels were related to impaired cognitive control functioning. This was not seen for the healthy controls. These findings suggest that schizophrenia patients have a glutamate-related dysregulation of the brain network supporting cognitive control functioning. This could be targeted in future research on glutamatergic treatment of cognitive symptoms in schizophrenia. (C) 2014 The Authors. Published by Elsevier Inc.